Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venlafaxine versus sertraline for depression in patients with epilepsy
IRCT20210608051515N2Phase 3Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of venlafaxine and sertraline in major depressive disorder (MDD) (2 arms), sponsored by Tehran University of Medical Sciences. Primary endpoints: Change in depression signs and symptoms associated with epilepsy, Change in seizure frequency and 1 more. Started Jul 2021; status: completed.
02
Drugs
venlafaxinesertraline
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on IRCT20210608051515N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20210608051515N2.